Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases. Founded by Stephane van Rooijen in 2016, Dynacure is backed by investors that include Andera Partners, Bpifrance, Kurma Partners, Perceptive Advisors, Pontifax, and Tekla Capital Management and is headquartered in Illkirch.